Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
SuO039LONG TERM EFFECTS OF OCTREOTIDE TREATMENT IN ADPKD PATIENTS WITH POLYCYSTIC LIVER DISEASE (A SUB-GROUP ANALYSIS OF THE ALADIN TRIAL) — Antonio Pisani (2015) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
SuO039LONG TERM EFFECTS OF OCTREOTIDE TREATMENT IN ADPKD PATIENTS WITH POLYCYSTIC LIVER DISEASE (A SUB-GROUP ANALYSIS OF THE ALADIN TRIAL)
Shared by
Giuseppe Remuzzi
SuO039LONG TERM EFFECTS OF OCTREOTIDE TREATMENT IN ADPKD PATIENTS WITH POLYCYSTIC LIVER DISEASE (A SUB-GROUP ANALYSIS OF THE ALADIN TRIAL)
Article
2015
en
Authors
+2 more
AP
Antonio Pisani
PR
Piero Ruggenenti
Giuseppe Remuzzi
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2016
Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease
Antonio Pisani
,
Massimo Sabbatini
,
Massimo Imbriaco
,
Eleonora Riccio
,
Nadia Rubis
,
Anna Prinster
,
Annalisa Perna
,
Raffaele Liuzzi
,
Letìzia Spinelli
,
Michele Santangelo
,
Giuseppe Remuzzi
,
Piero Ruggenenti
,
Antonio Pisani
,
Massimo Sabbatini
,
Piero Ruggenenti
,
Giuseppe Remuzzi
,
Antonio Pisani
,
Bianca Visciano
,
Maria Amicone
,
Renata Angela DiPietro
,
Giusi Rosaria Mozzillo
,
Eleonora Riccio
,
R. Rossano
,
Massimo Sabbatini
,
Letìzia Spinelli
,
Michele Santangelo
,
Nadia Rubis
,
Olimpia Diadei
,
Wally Calini
,
Alessandro Villa
,
Mary Ellen Sabatella
,
Bogdan Ene‐Iordache
,
Sergio Carminati
,
Davide Martinetti
,
Giovanni Giuliano
,
Annalisa Perna
,
Raffaele Liuzzi
,
Andrea Remuzzi
,
Massimo Imbriaco
,
Anna Prinster
,
M. Altiero
,
Paola Boccardo
,
S. Peracchi
Article
2018
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial
Letìzia Spinelli
,
Antonio Pisani
,
Giuseppe Giugliano
,
Bruno Trimarco
,
Eleonora Riccio
,
Bianca Visciano
,
Giuseppe Remuzzi
,
Piero Ruggenenti
Article
2019
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial
Norberto Perico
,
Piero Ruggenenti
,
Annalisa Perna
,
Anna Caroli
,
Matias Trillini
,
Sandro Sironi
,
Antonio Pisani
,
Eleonora Riccio
,
Massimo Imbriaco
,
Mauro Dugo
,
Giovanni Morana
,
Antonio Granata
,
Michele Figuera
,
Flavio Gaspari
,
Fabiola Carrara
,
Nadia Rubis
,
Alessandro Villa
,
Sara Gamba
,
Silvia Prandini
,
Monica Cortinovis
,
Andrea Remuzzi
,
Giuseppe Remuzzi
Article
2023
Effects of Octreotide–Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over Trial
Matias Trillini
,
Anna Caroli
,
Norberto Perico
,
Andrea Remuzzi
,
Paolo Brambilla
,
Giulia Villa
,
Annalisa Perna
,
Tobia Peracchi
,
Nadia Rubis
,
Davide Martinetti
,
Rosa Caruso
,
Valentina Fanny Leone
,
Daniela Cugini
,
Fabiola Carrara
,
Giuseppe Remuzzi
,
Piero Ruggenenti
Article
2022
Octreotide Lar in Patients with Autosomal Dominant Polycystic Kidney Disease: From Bench to A Novel Perspective of Therapy
Piero Ruggenenti
,
Annalisa Perna
,
Anna Caroli
,
Norberto Perico
,
Mattias Trillini
,
Antonio Pisani
,
Letìzia Spinelli
,
Giuseppe Remuzzi
Discussion(0)
No comments yet. Be the first to comment.